5 studies found for: Pilot Study of Redirected Autologous Tcells Engineered to Contain Anti-CD19
CD19 Redirected Autologous T Cells for Hodgkin Lymphoma
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
|3||Active, not recruiting||
CART-19 for Multiple Myeloma
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
† Study has passed its completion date and status has not been verified in more than two years.